Seeking Alpha

Aegis still positive on CytRx, sees big upside

  • Aegis is out with some upbeat commentary on CytRx (CYTR +3%), noting that despite the appearance of "a higher incidence of adverse events on aldoxorubicin ... all grade 3 or 4 thrombocytopenia, mucositis, or nausea / vomiting events are manageable and resolve."
  • As for the PFS outlook for aldoxorubicin, analyst Ram Selvaraju says "numbers of patients completing either four or six cycles both favor" the drug which, when "coupled with the 22% versus 0% PR rate favoring aldox may be predictive of positive PFS data."
  • Price target is $7 (so, upside of 200%+ from Friday's close).
  • For more on the data Selvaraju is referencing, see here.
From other sites
Comments (1)
  • mitrado
    , contributor
    Comments (2018) | Send Message
     
    Hmmm... does this means it will trade around $0.7 in a near future? (I completely distrust these PTs.)

     

    Just to remind some price targets (set not too long ago):

     

    $AMRN PT: > $30
    Reality: $1.7

     

    $DNDN PT: > $18
    Reality: $2.76

     

    $SRPT PT: > $50
    Reality: $15.87

     

    $SPPI PT: > $30
    Reality: $9.47

     

    Tell me again, why should I trust Price Targets for Bio-Tech companies?
    25 Nov 2013, 10:00 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs